Recent advances suggest that phase transitions of proteins into liquid or hydrogel states could underlie pathological protein aggregation associated with neurodegenerative disease. In a recent issue of Neuron, Murakami et al. (2015) demonstrate that ALS-associated FUS mutations abrogate the reversibility of condensed liquids and/or hydrogels, leading to neurotoxicity in C. elegans.
Many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), are marked by the formation of insoluble protein aggregates throughout the nervous system. However, an understanding of the biogenesis of protein aggregation and the mechanism by which the aggregation process impacts neuronal dysfunction remains elusive. RNA-binding proteins such as FUS, TDP-43, and hnRNPA1 are implicated in pathological aggregation in ALS and fronto-temporal dementia (FTD). Interestingly, these proteins normally function in the assembly of stress granules, RNA/protein (RNP) assemblies that exhibit dynamic liquid-like behavior. In a recent issue of Neuron, Murakami et al. (2015) demonstrate that ALS-associated FUS mutations contribute to neurotoxicity by promoting the formation of irreversible protein phases (Figure 1 ).
Phase transitions of proteins into condensed liquid or hydrogel states is emerging as a ubiquitous process underlying intracellular organization and its pathological dysregulation. Intrinsically disordered protein (IDP)/low complexity (LC) domains of RNA-binding proteins have been shown to drive phase transitions into either liquid droplets or hydrogels. In agreement with several other reports (Altmeyer et al., 2015; Burke et al., 2015; Lin et al., 2015; Patel et al., 2015; Xiang et al., 2015) , Murakami et al. (2015) show that FUS can phase-separate into liquid droplets and hydrogels in a manner dependent on its LC domain. However, they find that FUS disease mutants impact the degree of reversibility of FUS phases. While WT FUS can cycle between gel and solution states upon several cycles (5) of cooling and heating, FUS gels assembled from G156E and S96Del mutants could not be completely reversed. Similarly, FUS WT liquid droplets remix into a homogenous phase upon warming, while FUS mutants do not.
A challenge facing this new field is to connect in vitro protein phase behavior with in vivo cellular and organismal processes. Murakami et al. (2015) make progress in bridging this gap by characterizing solubility states and retention of accessory proteins across FUS droplets, gels, and assemblies of FUS protein expressed in the C. elegans nervous system ( Figure 1) . Analysis of C. elegans lysates revealed distinct features of WT and mutant FUS assemblies in vivo: while WT FUS is fully soluble in worm lysate prepared in standard high-salt RIPA buffer, harsh 8M urea treatment was required to fully solubilize mutant FUS assemblies. Notably, the degree of insolubility correlates with a decrease in lifespan and neuronal motor function measured by a worm thrashing score. Using an RNAi screen, two proteins associated with neuronal toxicity, SMN and STAU-1, were identified and found to colocalize with FUS mutant assemblies, but not wild-type FUS. Remarkably, both the RIPA/urea solubility patterns and localization of SMN and STAU-1 proteins are mirrored in vitro, with the recombinant FUS liquid droplets and hydrogels. The authors conclude that retention of additional proteins within irreversible FUS assembly states plays an important role in neurotoxicity.
The work of Murakami et al. (2015) is consistent with a flurry of recent papers demonstrating that numerous IDP/LC proteins drive phase separation into liquid droplets with malleable properties (Elbaum-Garfinkle et al., 2015; Lin et al., 2015; Molliex et al., 2015; Nott et al., 2015; Patel et al., 2015; Zhang et al., 2015) . The current work further supports the hypothesis that gelation of in vivo liquid phase assemblies is associated with neurodegeneration. The dynamics of this process are challenging to dissect in vivo. A newly described tool for assaying protein conformational state both in vitro and in vivo (Xiang et al., 2015) could be useful for determining how liquid phase assemblies may convert to pathological fibers and/or gels in vivo. More experiments are needed to decipher the unique and shared characteristics of phase-separated liquids and gels, as well as their respective contribution to function and pathology.
Most previous studies have reported phase transitions into liquid droplets or gels that are completely reversible, in notable contrast to the irreversiblyassembled amyloid fibers associated with disease. However, the irreversible FUS assemblies described by Murakami et al. (2015) are also different from classic amyloids in that they do not interact with amyloid-sensitive dyes and are soluble in urea. Thus, regardless of the structural state of the protein within intracellular assemblies, irreversibility may serve as a more useful metric of toxicity for future studies.
Biological function requires dynamic molecular interactions. Irreversible, solid-like protein assemblies are therefore expected to have detrimental effects on cellular function. Sequestering of proteins and RNA could serve to repress translation or simply disrupt functions that depend on the cytoplasmic abundance of particular proteins. To test whether FUS mutant assemblies serve as translational repressors, Murakami et al. (2015) demonstrate that mutant FUS neurons experienced a significant reduction in protein synthesis. This suggests that mutant FUS assemblies may be pathological due to sequestration of components necessary for RNA metabolism and translation.
Moving forward, it will be exciting to discern how liquid-phase RNP assemblies are regulated and maintained in vivo to avoid irreversible pathological transitions. The heterogeneous molecular composition of in vivo assemblies is a likely factor in avoiding pathogenicity. RNA can tune the material properties of RNP droplets Zhang et al., 2015) , suggesting that the presence or absence of RNA could impact pathogenic aging of droplets. It will also be interesting to see how chaperone and disaggregase activity, along with stress-or age-associated proteostasis breakdown, could influence droplet assembly and properties. Determining the biophysical and intracellular regulatory mechanisms governing RNP phase transitions into liquid and gel-like states should lead to new approaches for therapies aimed at inhibiting or reversing neurotoxic protein aggregation. wild-type protein can assemble into liquid or hydrogel states that can be fully reversed to a mixed bulk solution. FUS ALS/FTD mutations lead to assembly of liquids and/or gels that can no longer be reversed, resulting in the retention of additional proteins. This insoluble, irreversible protein phase correlates with deteriorated motor nerve function and decreased lifespan, characteristic of ALS/FTD diseases.
